Jommi, C., and M. Cavazza. “Management of Patients Eligible for Proprotein Convertase subtilisin/kexin Type 9 (PCSK9) Inhibitors: Economic Impact and Reform Proposals”. Global and Regional Health Technology Assessment, vol. 6, no. 1, July 2019, doi:10.33393/grhta.2019.460.